Fondaparinux (Arixtra) With Chemotherapy for Advanced Non-Small Cell Lung Cancer

Inclusion Criteria: * Histologic or cytologic diagnosis of Non-Small Cell Lung Cancer. * Stage IV Non-Small Cell Lung Cancer. * Measurable or assessable tumor parameters according to RECIST criteria. * ECOG Performance Status 0-2. * Age between 18 and 79 years (in the State of Alabama \> 18). * Adequate hematologic, coagulation, liver and renal function, defined as: * Absolute neutrophil count (ANC) ≥ 1500/µL * Platelet count ≥ 100,000/µL * Serum Glutamic Oxaloacetic Transaminase(SGOT)/Serum Glutamic Pyruvic Transaminase(SGPT) ≤ 2.5 x upper limit of normal or ≤ 5 x upper limit of normal when liver metastases are present * Total bilirubin value ≤ 1.5 x upper limit of normal * Serum creatinine value ≤ 1.5 x upper limit of normal * Normal prothrombin time and partial thromboplastin time * Fully recovered from any previous surgery (at least 4 weeks since major surgery). * Must have recovered from prior radiation therapy (at least 3 weeks). * All participants must agree to practice approved methods of birth control (if applicable). A negative pregnancy test must be documented during the screening period for women of childbearing potential. * Must provide written informed consent and authorization to use and disclose health information. * No prior chemotherapy. Exclusion Criteria: * Active bleeding disorder. * Evidence of hemoptysis. Patients with blood-tinged or blood-streaked sputum will be permitted on study if the hemoptysis amounts to less than 5 mL of blood per episode and less than 10 mL of blood per 24-hour period in the best estimate of the investigator. * Previous history of Venous Thromboembolism (VTE) within 12 months and requiring active anticoagulation therapy. * Concurrent cancer chemotherapy, biologic therapy or radiotherapy. * Administration of any investigational drug within 28 days prior to administration of the current therapy. * Symptomatic brain metastases; those patients should be treated first with either whole brain radiation therapy or radiosurgery and have stable disease. * Concurrent serious infection. * Concomitant severe or uncontrolled underlying medical disease unrelated to the tumor, which is likely to compromise patient safety and affect the outcome of the study. * History of other malignancy (except non-melanoma skin cancer or carcinoma in situ of the cervix), unless in complete remission and off all therapy for a minimum of 2 years. * Any evidence or history of hypersensitivity or other contraindications for the drugs used in this trial. * Psychiatric disorder that prevents patients from providing informed consent or following protocol instructions. * Pregnant or lactating women. * Creatinine clearance \< 30 mL/min. * Patient body weight \< 50 kg.